STUDresearch · Non-peptide
NR (Nicotinamide Riboside)
Also known as
Nicotinamide riboside · Nicotinamide riboside chloride · NR chloride · NRCl · Niagen · Niagen NR · Tru Niagen · Vitamin B3 riboside form · NRPT (NR + pterostilbene blend; Basis-class) · Nicotinamide ribose (common misspelling)
Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.
Non-peptide
Some talk
Systemic
Oral
Longevity & cellular energy
Systemic oral NAD+ precursor.
What people say
Longevity and biohacking discussions use NR as a vitamin-B3 route to raising blood NAD+. It is not a peptide, an IV NAD+ treatment or proven human lifespan therapy.
Doses people talk about
Reported amounts, not a progression. Labels may state NR chloride salt or free-base equivalents, and co-ingredients vary. Gram-level research and IV/IM/SubQ pilots remain separate in the full notes.
How it may feel
Often no acute buzz. Reports include energy or clarity over weeks, no discernible benefit, and worsening fatigue. One two-week negative account also used polyphenols; other posters reported neutral or positive experiences.
Consumer-label / forum amount~250–300 mg once daily
Oral Niagen-class examples often use one 300 mg capsule. One actual 300 mg account also included 250 mg polyphenols; experience cannot be assigned to NR alone.
Higher community daily total~500–1000 mg/day oral
A separate discussion band, not an instruction to increase from a lower amount.
NRPT mixed-product example~250 mg NR + ~50 mg pterostilbene/day
5:1 component ratio; a double trial arm used ~500 mg NR + ~100 mg pterostilbene. These are not single-ingredient NR amounts.
Half-life & effect duration
- Half-life in the body
- Whole-blood NR · study estimateAbout 2.7 hours
- Felt duration people report
- AccountsPositive effects, no change or fatigue
- One combination accountWorsening fatigue after 2 weeks
- Other accountsYears without fatigue, or no difference at 2 weeks
Cycles people discuss
Daily months-to-years use and 4–12-week trial-style checks both appear in longevity discussion. Off-periods are often about cost or reassessment; neither a cycling calendar nor a loading reload is established.
Timing
Morning use with or without food is common. Some people move later doses earlier when sleep feels lighter, while food is used mainly for GI comfort; these are convenience and tolerance habits, not a proven best clock.
Stacks
NR is discussed alone or with pterostilbene, NMN, resveratrol and methyl donors. TMG is treated as optional insurance in some stacks, not a proven requirement; mixed formulas confound both benefit and GI effects.
Watch for
GI (most common cluster): Nausea, bloating, gas, indigestion, loose stools/diarrhea — usually mild; more noticeable as daily totals climb into multi-hundred-mg to gram ranges or multi-capsule BID schedules.
Tap a line for the full notes and source context.
Timing context & sources
Half-life in the body
An estimated 2.7 hours in four participants with distinct whole-blood NR peaks.
The eight-person escalation study reached 1000 mg twice daily. Only four had a clear declining peak from which this estimate was derived; downstream NAD+ and unstable collected samples are different endpoints.
Small, open-label study; not a universal 300 mg capsule, plasma, tissue or injected-NR half-life.
- Airhart et al. (2017): oral NR and blood NAD+ pharmacokinetics (opens in a new tab)Full article: Results, Assay development/NR measurements (sample instability); NR pharmacokinetics, day-9 3–12-hour decline in four of eight participants; Figure 3 and Discussion. Actual full text read.Small open-label dose-escalation study; the 2.7-hour estimate is whole-blood parent NR, not NAD+, and not derived in all eight participants.
Felt duration people report
No dependable onset or felt-duration clock: positive, neutral and fatigue reports conflict.
One poster described worsening fatigue after two weeks of morning NR plus polyphenols. Replies included years of use without fatigue and a neutral two-week NR/NMN account.
Self-selected reports, different formulations and co-supplements; NAD+ blood changes do not establish how long a person feels anything.
- More fatigue on Tru Niagen — my experience (opens in a new tab)October 13, 2023 OP PotentialOverall8071: 300 mg NR plus 250 mg polyphenols each morning, worsening fatigue after two weeks. Read OP and replies by jimw0z, vauss88, Bull_shit_artist and Few-Beginning-6183, including neutral/positive and co-intervention context.Unverified products, self-selection and co-supplements; no same-author outcome update was visible in the accessed thread. Reply experiences do not establish prevalence or causality.
What people say
- Energy feel: Users commonly report subtle daytime energy, less afternoon crash, or ‘background resilience’ rather than a stimulant high; placebo and concurrent lifestyle confounds are hard to rule out. forum
- Longevity base layer: Even when subjective change is small, many treat NR as a foundational NAD stack piece rather than a ‘feel it or quit’ nootropic. forum
- Blood NAD+ (most solid human signal): Oral NR raises whole-blood NAD+ and related metabolites, often within ~1–2 weeks, roughly dose-related across common trial bands. trial
- Conze-style dose map (overweight adults, 8 weeks): ~100 mg/day ≈ +22% whole-blood NAD+; ~300 mg/day ≈ +51%; ~1000 mg/day ≈ +142% by ~day 14, with increases largely sustained while dosing continued. trial
- Metabolic trials (mixed/nulls matter): In middle-aged obese insulin-resistant men, ~2000 mg/day for 12 weeks did not improve insulin sensitivity, body composition, or several metabolic clamp/GTT endpoints in published reports — a frequently cited caution against overselling metabolic miracles. trial
- Muscle NAD caveat: Same high-dose metabolic work reported skeletal-muscle NAD+/related nucleotides largely unchanged despite blood metabolome shifts — so ‘blood NAD up ≠ every tissue up’ is a fair research summary. trial
- Vs niacin flush: Trials and labels emphasize little-to-no classic nicotinic-acid flush at usual NR doses — a major preference reason vs high-dose niacin. trial
- Cognition / brain aging: Exploratory and disease-population work exists; controlled cognitive primaries in general populations often null or modest. trial
- Long-COVID / fatigue research: A controlled trial used ~2000 mg/day and reported large NAD+ rises (~2.6–3.1× in at least ~5 weeks) with symptom/cognitive endpoints interpreted cautiously; AEs similar to placebo in that report. trial
- Parkinson’s research interest: NADPARK (~1000 mg/day, ~30 days) increased NAD metabolome / cerebral NAD signals with exploratory clinical interest; NR-SAFE tested ~3000 mg/day (1500 mg BID) for safety in PD with exploratory MDS-UPDRS signals that authors noted could be partly confounded by levodopa timing. trial
- Inflammation narrative: Some human and mechanistic work is discussed for anti-inflammatory NAD-related signals; not a settled pan-anti-inflammatory claim. trial
- Animal models: Rodent data are widely cited for metabolic, neuro, and stress-resilience endpoints — useful for mechanism talk, not automatic human effect sizes. animal
- Sparse honesty: Raising blood NAD+ is far better supported than durable disease modification, performance gains, or lifespan extension in healthy humans. trial
Doses people talk about
- Higher community band: ~500–1000 mg/day oral is frequently discussed as the range where longevity influencers and some trial-informed users report using; some describe reaching it after a lower amount, but that is not a dose progression validated by these accounts. forum
- Timing: Morning with or without food is the common default; some move later dosing earlier if sleep feels lighter — sleep effects are inconsistent anecdotes, not a fixed PK rule. forum
- With food vs empty: Product directions vary; food is often used for GI comfort at higher capsule counts rather than proven NAD synergy. forum
- No loading protocol: Community and trials generally start at the intended daily band rather than a short mega-load then taper. forum
- Ceiling talk: Some commentary argues blood NAD+ may approach a practical ceiling near ~1000 mg/day of a single precursor for many people — stacking a second precursor may add cost more than NAD; this is inference from limited head-to-heads, not a universal law. forum
- NR + NMN dual (expert/podcast lore): Discussed as optional ‘insurance’ at modest splits (e.g., ~250 mg each) without a clear human trial proving superior NAD rise vs a full trial dose of either alone. forum
- Consumer-label / forum band: ~250–300 mg once daily is presented as a starting amount in Tru Niagen–class marketing and many forum starts (often one 300 mg capsule). forum
- Basis / NRPT marketed pair: Common commercial unit is ~250 mg NR + ~50 mg pterostilbene per day (5:1 NR:PT); trial arms also used double (~500 mg NR + ~100 mg PT). trial
- Trial NAD map (once-daily oral, Conze et al.–class): 100 / 300 / 1000 mg/day produced roughly dose-related whole-blood NAD+ rises (~+22% / +51% / +142% by ~2 weeks), supporting ‘more NR → more blood NAD+’ within this span. trial
- High trial band: ~1000–2000 mg/day oral appears in multiple metabolic, aging, and symptom trials; often split BID in study designs and capsule-burden discussions; a split schedule is not proof of superior felt coverage. trial
- Very high safety exploration: NR-SAFE used 1500 mg twice daily (3000 mg/day total) for 4 weeks in Parkinson’s (Tru Niagen capsules 250 mg) and supported extending phase II dose range to 3000 mg/day with monitoring — not a standard consumer ‘blast.’ trial
- Escalation PK pilot pattern: Early human work escalated oral NR from ~250 mg up through ~2000 mg over about a week then assessed steady-state-style blood exposure — shows wide inter-individual NR/NAD response scatter. trial
- Split dosing practice: BID splits dominate higher multi-capsule regimens (e.g., 4×250 mg morning + 4×250 mg evening for 2000 mg/day designs) in adherence and between-dose-exposure discussions; the schedule itself does not establish better symptoms or an individual requirement. trial
- Injectable / IV NR (emerging clinic talk): Pilot work has explored acute IV ~500 mg NR and multi-day IM/SQ ~50–100 mg NR regimens; these are not the evidence base behind oral consumer dosing charts. trial
- Upper-bound honesty: Short trials support tolerability into gram-level oral doses for many participants; long-term multi-year safety and disease-outcome proof at those doses remain thinner. trial
- Framing: Research and community ranges only — not medical advice, not a personal protocol. Product ‘mg’ may mean NR chloride salt vs free-base equivalence; labels and third-party assays vary. forum
How it may feel
- Day 0 expectation setting: Most public logs describe no acute ‘on’ like caffeine; first-week silence is normal, not proof the product is fake. forum
- Days 1–7: Often nothing subjective; minority mild GI (nausea, bloating, loose stool) or headache/fatigue in AE tables and logs. In a separate October 2023 thread, one poster described worsening fatigue, weakness and word-finding after two weeks of 300 mg NR plus 250 mg polyphenols each morning; replies included neutral or positive long-term experiences. The co-product and uncontrolled reports prevent attribution to NR alone. trialanecdote
- Weeks 3–4: Common community checkpoint: posters describe continuing vitamin-style maintenance, changing amounts within discussed bands, or stopping for cost/null feel; these are choices reported in logs, not instructions. forum
- Weeks 4–12: Matches many trial windows used for energy feel, NAD-adjacent labs, or metabolic endpoints; subjective plateau more common than escalating highs. forum
- No subjective change by 4–8 weeks: Still compatible with rising blood NAD+; marketing ‘feel younger in days’ expectations often mismatch trial reality. forum
- After stop: Many notice nothing; some report soft return of fatigue or ‘less resilience’ over days–weeks — uncontrolled anecdotes. anecdote
- Week 1–2: Blood NAD+ often already up in trials; any energy/clarity reports often start here — or never appear despite labs. trial
- Month 2–3+: Background support framing dominates; continuous daily use is the longevity default, not a cycling ‘blast.’ forum
Cycles people discuss
- Continuous daily (dominant longevity pattern): Treated like a daily vitamin/NAD foundation — open-ended months to years rather than bodybuilding on/off cycles. forum
- Trial-style blocks: 4–12 weeks common when someone is testing subjective energy, labs (NAD-related panels if available), or cost-benefit. forum
- Restart: Community restart discussions describe returning to prior daily mg; no widely accepted loading reload is established. That reported practice is not a restart recommendation. forum
- Bloodwork curiosity (not required by forums): Homocysteine, lipids, basic metabolic/liver panels, and optional NAD metabolome tests get discussed when people run high doses or stacks with methyl donors / pterostilbene. forum
- Parkinson / clinical research blocks: Examples include ~30 days at 1000 mg/day (NADPARK) and ~4 weeks at 3000 mg/day (NR-SAFE) — research schedules, not consumer cycles. trial
- Metabolic study length example: ~12 weeks at 2000 mg/day in obese insulin-resistant men is a key published duration for ‘null metabolic hard endpoints despite NAD rise’ discussions. trial
- High-dose short runs: Multi-week gram-level use is mostly clinical-trial or aggressive experiment territory, not a standardized ‘blast and cruise.’ trial
- Off periods: Taken for cost, lab resets, or skepticism; others never off if framing is lifelong NAD maintenance. forum
Timing
- Why daily (or BID) dosing: Goal is sustained support of the NAD+ pool and related metabolome while intake continues — not a multi-day depot of intact NR. forum
- After last dose: NAD+ elevation is not assumed to persist indefinitely; community reports and trial logic treat benefits as contingent on ongoing intake. forum
- Feel lag: Subjective change, if any, often trails measurable NAD shifts by days–weeks; many never feel a sharp on/off. forum
- Parent NR in whole blood: The often-cited ~3-minute figure should not be read as an established human oral elimination half-life; its original measurement context is unresolved here. In the 2017 eight-person oral escalation study, four participants with distinct peaks yielded an estimated 2.7-hour whole-blood NR half-life from the 3–12-hour decline after the day-9 morning dose. NR conversion toward nicotinamide, sample instability and NAD+ persistence are distinct observations. trial
- Between-dose behavior: Early PK work showed NR itself can peak and trough within ~12-hour BID windows even when average exposure looks elevated; NAD+ in blood can look steadier than parent NR. trial
- NAD+ rise window: Whole-blood NAD+ commonly elevated by ~1–2 weeks of daily oral use and maintained while dosing continues in multi-week trials. trial
- Individual PK scatter: Same oral mg can produce highly variable NR/NAD responses — responder/non-responder talk appears in early human PK notes (gut conversion, transport, microbiota hypotheses). trial
- Tissue lag / mismatch: Blood NAD+ can rise while skeletal muscle NAD measures stay flat in some high-dose work — feel and tissue biochemistry may lag or diverge from blood. trial
- Downstream excretion: Urine methylated nicotinamide metabolites (e.g., MeNAM, Me2PY, Me4PY class) rise with NR intake in trials — part of why methyl-budget talk exists even when homocysteine often does not move. trial
More on what it is
- Why people use it: Longevity and biohacking communities treat NR (Niagen / Tru Niagen class) as a mainline way to raise blood NAD+ without classic high-dose niacin flush. forum
- What it is: A form of vitamin B3 (usually as nicotinamide riboside chloride) sold as an oral NAD+ precursor — not a peptide, not IV NAD+, not a prescription anti-aging drug. trial
- Mechanism (simple): Enters the NAD salvage path via NR kinases (NRK1/NRK2) toward NAD+; forums shorthand this as ‘sirtuin/mito fuel.’ trial
- Parent versus downstream pools: NR can convert toward nicotinamide and related metabolites, and intact NR is unstable in unstabilized blood samples. That sample-handling issue is not a minutes-long human oral elimination estimate: a small oral study estimated a 2.7-hour whole-blood NR half-life in four participants with distinct peaks. The longer-lived NAD+ pool is a separate endpoint, not a multi-day NR depot. trial
- Evidence honesty: Human trials consistently raise blood NAD+ metabolites; hard clinical wins (body comp, insulin sensitivity, cognition, lifespan) are mixed, modest, or null depending on endpoint and dose. trial
- What it is not: Not proven human lifespan therapy; not a stimulant; not interchangeable with clinic NAD+ IVs or with NMN on a milligram-for-milligram basis without context. trial
Stacks
- NR alone (cleanest trial mirror): Many prefer single-ingredient Niagen-class NR to match published dose–NAD maps without co-ingredient confounds. forum
- NR + NMN dual stack: Used as ‘coverage insurance’ at modest splits; no robust human trial shows stacking both beats a full dose of either alone for NAD+. forum
- Resveratrol: Classic sirtuin-stack folklore with NR; some researchers argue weak evidence for the pairing and note possible interference narratives in specific disease contexts — community remains split. forum
- Broader longevity mix: Quercetin, fisetin, urolithin A, CoQ10, omega-3s, creatine, sleep hygiene — common ‘kitchen sink’ plans that confound any single-agent credit. forum
- Metformin / berberine–adjacent metabolic plans: Discussed in the same longevity circles; drug interactions and glucose effects are clinician-territory, not forum dosing charts. forum
- Training stacks: Creatine, electrolytes, protein, zone-2 cardio — outcomes rarely isolatable to NR. forum
- Avoid overstacking two full gram-level precursors + polyphenols + methyl donors on day one: Cost and GI load rise faster than proven synergy. forum
- NR + pterostilbene (NRPT / Basis-class): Flagship marketed pair — classic ratio ~250 mg NR : 50 mg pterostilbene (1×) or ~500 : 100 (2×). Sirtuin/NAD narrative; some experts later question pterostilbene’s necessity and note dose-related LDL concerns in critiques. trial
- NR vs NMN (comparison more than synergy): Endless head-to-head threads. Both raise NAD-related markers in humans; route, regulation history, cost, and brand wars dominate. A Norway crossover-style report discussed at same gram dose (~1200 mg/day class) has been cited by NR-aligned sources as favoring NR for whole-blood NAD+ rise — still one data slice, not settled consensus. trial
- Methyl donors (TMG / betaine, folate, B12): Theory: high NAD-precursor flux increases nicotinamide clearance/methylation demand. Practice: often 500–3000 mg TMG discussed in broader NAD stacks. Counter-evidence: multiple NR trials (including higher doses) did not show harmful homocysteine or methylation disruption, including some MTHFR-variant analyses — so TMG is ‘insurance,’ not proven mandatory with NR. trial
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Cancer / proliferation discourse: Theoretical caution that NAD+ support could be undesirable in active malignancy — forum/expert risk talk, not a filled human harm table for standard supplemental use. forum
- Product quality: Identity, actual NR content, chloride salt labeling, and co-ingredients vary; patented Niagen supply chain is often preferred in quality-focused threads; third-party testing is uneven across generics. forum
- Pregnancy / lactation / pediatric: Not charted as forum protocols; systematic safety data insufficient for casual use talk. forum
- Drug interactions / special populations: Limited systematic interaction tables; clinicians are the right layer for polypharmacy, active cancer, advanced liver/kidney disease, or complex neuro meds. forum
- GI (most common cluster): Nausea, bloating, gas, indigestion, loose stools/diarrhea — usually mild; more noticeable as daily totals climb into multi-hundred-mg to gram ranges or multi-capsule BID schedules. trial
- Headache / fatigue / mild malaise: Appear in AE tables and user logs; not always separable from placebo rates in every study. trial
- Example safety trial AE flavor (Conze-class reporting in secondary summaries): Mild nausea, headache, and diarrhea each in roughly high-single to low-double-digit percent ranges at higher doses — illustrative, study-specific, not a universal rate card. trial
- Flush / skin: Classic nicotinic-acid flush is uncommon with NR vs high-dose niacin; occasional mild flush, warmth, or rash still reported especially at higher doses. trial
- Lipids / triglycerides: At least one high-dose metabolic trial noted increased plasma triglycerides with ~2000 mg/day NR; lipid panels get discussed when stacking pterostilbene (LDL concern in some critiques) or high TMG. trial
- Liver enzymes: Generally without clinically alarming group signals in short trials; modest within-range shifts have been mentioned in secondary safety write-ups at higher doses — monitor if stacking or clinically vulnerable. trial
- Methylation / homocysteine discourse: Theoretical methyl sink from NAM clearance; human NR data often show no meaningful homocysteine rise or DNA-methylation disruption even at high dose or with common MTHFR variants — TMG remains optional insurance in bro stacks, not a proven NR requirement. trial
- Parkinson’s high-dose caveats: NR-SAFE supported short-term high-dose tolerability but authors cautioned exploratory motor-score improvements could be influenced by levodopa timing differences — do not treat as proven PD disease-modifying therapy. trial
- Metabolic nulls as caution against hype: Failure to move insulin sensitivity / body composition / muscle NAD in key trials is itself a ‘side’ of expectation management. trial
- Well tolerated ≠ free or proven: Short-to-medium trials often show AE rates near placebo; that is not multi-year proof for every longevity claim or every product on the market. trial
- Injectable/IV clinic routes: Different AE surface (infusion reactions, injection-site issues) than oral capsules; pilot safety ≠ established superiority for aging endpoints. trial
Evidence mix
More trial/lab tags than forum tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.